Kinetic studies. All reactions were carried out with uniformly [α - 32 P]ATP-labelled ribozyme and excess AMP-aminoacyl-Bio substrate (≥ 100 -fold) in 50 mM HEPES (pH 7.4), 300 mM KCl and 50 mM MgCl₂ at 25 °C. The RNA was preincubated with buffer and Mg²⁺ for 10 min at 50 °C, and cooled to room temperature (~20 min). The reaction was initiated by addition of AMP-aminoacyl-Bio substrate. At each time point, 7 or 8 aliquots of 2 μ l were removed from 20 μ l reaction mixtures and quenched in dry ice with one volume of 'stop' buffer containing 100 mM HEPES (pH 7.4) and 100 mM EDTA. Samples were incubated with 10 μ g streptavidin in binding buffer at room temperature before mixing with 0.25 volumes of 90% formamide loading buffer. Biotinylated RNA products were separated by electrophoresis on 8% polyacrylamide/7 M urea gels (1,000 V at 4 °C for 2 h). The fraction of product formation relative to total substrate and product at each time point was quantified with a Molecular Dynamics PhosphorImager. Reactions reached 30–50% completion and rates were corrected for this end point.

Received 6 August; accepted 17 September 1997.

1. Woese, C. R. In *The Genetic Code: The Molecular Basis for Genetic Expression* 179–195 (Harper & Row, New York, 1967).
2. Crick, F. H. C. The origin of the genetic code. *J. Mol. Biol.* **38**, 367–379 (1968).
3. Noller, H. F. In *The RNA World* (eds Gesteland, R. F. & Atkins, J. E.) 137–156 (Cold Spring Harbor Laboratory Press, Plainview, NY, 1993).
4. Noller, H. F., Hoffarth, V. & Zimmick, L. Unusual resistance of peptidyl transferase to protein extraction procedures. *Science* **256**, 1416–1419 (1992).
5. Ellington, A. D. & Szostak, J. W. *In vitro* selection of RNA molecules that bind specific ligands. *Nature* **346**, 818–822 (1990).
6. Robertson, D. L. & Joyce, G. F. Selection *in vitro* of an RNA enzyme that specifically cleaves single-stranded DNA. *Nature* **344**, 467–468 (1990).
7. Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science* **249**, 505–510 (1990).
8. Bartel, D. P. & Szostak, J. W. Isolation of new ribozymes from a large pool of random sequences. *Science* **261**, 1411–1418 (1993).
9. Lorsch, J. R. & Szostak, J. W. *In vitro* evolution of new ribozymes with polynucleotide kinase activity. *Nature* **371**, 31–36 (1994).
10. Prudent, J. R., Uno, T. & Schultz, P. G. Expanding the scope of RNA catalysis. *Science* **264**, 1924–1927 (1994).
11. Dai, X.-C., de Mesmaeker, A. & Joyce, G. F. Cleavage of an amide bond by a ribozyme. *Science* **267**, 237–240 (1995).
12. Illangasekare, M., Sanchez, G., Nickles, T. & Yarus, M. Aminoacyl-RNA synthesis catalyzed by an RNA. *Science* **267**, 643–647 (1995).
13. Wilson, C. & Szostak, J. W. *In vitro* evolution of a self-alkylating ribozyme. *Nature* **374**, 777–782 (1995).
14. Eklund, E. H. & Bartel, D. P. RNA-catalysed RNA polymerization using nucleoside triphosphates. *Nature* **382**, 373–376 (1996).
15. Lohse, P. A. & Szostak, J. W. Ribozyme-catalysed amino-acid transfer reactions. *Nature* **381**, 442–444 (1996).
16. Wecker, M., Smith, D. & Gold, L. *In vitro* selection of a novel catalytic RNA: characterization of a sulfur alkylation reaction and interaction with a small peptide. *RNA* **2**, 982–994 (1996).
17. Nierhaus, K. H., Schultz, H. & Cooperman, B. S. Molecular mechanisms of the ribosomal peptidyltransferase center. *Biochem. Int.* **1**, 185–192 (1980).
18. Pyle, A. M. Ribozymes: a distinct class of metalloenzymes. *Science* **261**, 709–714 (1993).
19. Maden, B. E. H. & Monro, R. E. Ribosome-catalyzed peptidyl transfer: effects of cations and pH value. *Eur. J. Biochem.* **6**, 309–316 (1968).
20. Piccirilli, J. A., McConnell, T. S., Zaug, A. J., Noller, H. F. & Cech, T. R. Aminoacyl esterase activity of the *Tetrahymena* ribozyme. *Science* **256**, 1420–1424 (1992).
21. Cech, T. R. In *The RNA World* (eds Gesteland, R. F. & Atkins, J. E.) 239–269 (Cold Spring Harbor Laboratory Press, Plainview, NY, 1993).
22. Bass, B. L. & Cech, T. R. Specific interaction between the self-splicing RNA of *Tetrahymena* and its guanosine substrate: implications for biological catalysis by RNA. *Nature* **308**, 820–826 (1984).
23. Sassanfar, M. & Szostak, J. W. An RNA motif that binds ATP. *Nature* **364**, 550–553 (1993).
24. Monro, R. E., Cerna, J. & Marker, K. A. Ribosome-catalyzed peptidyl transfer: substrate specificity at the P-site. *Proc. Natl Acad. Sci. USA* **61**, 1042–1049 (1968).
25. Mercer, T. F. B. & Symons, R. H. Peptidyl-donor substrates for ribosomal peptidyl transferase: chemical synthesis and biological activity of *N*-acetyl aminoacyl di- and trinucleotides. *Eur. J. Biochem.* **28**, 38–45 (1972).
26. Krayevsky, A. A., Kukhanova, M. K. & Gottikh, B. P. Peptidyl transferase center of bacterial ribosomes: substrate specificity and binding site. *Nucleic Acids Res.* **2**, 2223–2236 (1975).
27. Azharyev, A. V. *et al.* Synthesis of amino acid esters of nucleoside 5'-phosphates and their investigation with PMR and CD spectra. *Nucleic Acids Res.* **4**, 2223–2234 (1977).

Supplementary information is available on Nature's World-Wide Web site (<http://www.nature.com>) or as paper copy from Mary Sheehan at the London editorial office of Nature.

Acknowledgements. We thank K. Goodrich and E. Podell for oligonucleotide synthesis; R. Barkley and O. Averin for HPLC-MS spectra; and B. Golden, R. Gottlieb, G. Joyce, S. Seiwert and O. Uhlenbeck for comments on the manuscript. B.Z. is supported by a postdoctoral fellowship from the National Institute of General Medical Science, NIH. T.R.C. is an investigator of the Howard Hughes Medical Institute and an American Cancer Society Professor.

Correspondence and requests for materials should be addressed to T.R.C. (e-mail: thomas.cech@colorado.edu).

correction

Synthesis of epothilones A and B in solid and solution phase

K. C. Nicolaou, N. Winssinger, J. Pastor, S. Ninkovic, F. Sarabia, Y. He, D. Vourloumis, Z. Yang, T. Li, P. Giannakakou & E. Hamel

Nature **387**, 268–272 (1997)

We wish to add that, as well as a total synthesis of epothilone B, reference 19 includes biological data for compound **23** and other congeners similar to those reported in our Letter. □

retraction

High levels of genetic change in rodents of Chernobyl

Robert J. Baker, Ronald A. Van Den Bussche, Amanda J. Wright, Lara E. Wiggins, Meredith J. Hamilton, Erin P. Reat, Michael H. Smith, Michael D. Lomakin & Ronald K. Chesser

Nature **380**, 707–708 (1996)

We previously reported an elevated DNA substitution rate in the mitochondrial cytochrome *b* gene of voles from Chernobyl. Our conclusion was based on a higher level of variation in rodents living in the zone of radioactivity than in rodents from control regions. Those DNA sequences were obtained by manual sequencing of cloned PCR products. We have subsequently attempted to replicate these findings with direct, automated sequencing of PCR products from the same animals. We found discrepancies between these sequences generated by direct automated methods and those previously reported. Re-examination of the original autoradiograms revealed that the elevated levels of variation were largely a product of human error in scoring, aligning and recording the sequences. This error has been confirmed by automated sequencing of a selected sample of the original clones on which the manual sequences were based. There remains a higher rate of substitution in the nine animals from the radioactive zone than in the ten animals from the control population, but the difference is not statistically significant with this sample size. There is variation among the clones from the mice living in the radioactive regions, including clones from the embryos. The two mutations reported in the embryos do not qualify as substitutions based on the standard set forth in the methods and materials that changes be present in multiple clones. The significance (if any) of this variation remains to be determined. The data do not support a mutation rate as high as that reported, and we retract that conclusion. □

magnetoresistive component in CMR materials arising at grain boundaries at high temperatures.

Our highly symmetric Wheatstone-bridge structures afford new insight into the underlying mechanisms that contribute to CMR phenomena. The technique is able to isolate the specific contribution of a single grain boundary and quantify the role of the imposed magnetic substructure. In addition, the discovery of a positive magnetoresistance at higher temperatures underlines the significance of the cross-over between transport regimes near T_c . The dramatic effect induced by the introduction of a single grain boundary demonstrates the extreme sensitivity of the electrical conduction processes in CMR materials to microstructural defects, and the results should stimulate further experimental and theoretical study of these materials.

The potential applications of CMR materials have been limited up to now by the very high magnetic fields required to induce significant changes in resistance. Our findings immediately provide a method by which controllable low-field magnetoresistive devices may be simply fabricated from CMR materials. Moreover, such devices would have the potential to operate beyond the narrow range of operating temperatures of more simply configured CMR material systems and at lower absolute resistivities. The fields required to induce the low-field magnetoresistance in the grain boundary devices are comparable to those required for existing magnetoresistive structures such as spin valves. The use of high- T_c materials (such as $\text{La}_{0.7}\text{Sr}_{0.3}\text{MnO}_3$) should permit room-temperature operation, and a greater understanding of the basic physics and improvements in materials properties are likely to increase the magnetoresistance achievable. □

Received 4 February; accepted 25 March 1997.

- Jin, S. *et al.* Thousandfold change in resistivity in magnetoresistive La–Ca–Mn–O films. *Science* **264**, 413–415 (1994).
- von Helmholt, R., Wecker, J., Holzappel, B., Schultz, L. & Samwer, K. Giant negative magnetoresistance in perovskitelike $\text{La}_{2/3}\text{Ba}_{1/3}\text{MnO}_x$ ferromagnetic films. *Phys. Rev. Lett.* **71**, 2331–2334 (1993).
- Subramanian, M. A. *et al.* Colossal magnetoresistance without $\text{Mn}^{3+}/\text{Mn}^{4+}$ double exchange in the stoichiometric pyrochlore $\text{Ti}_2\text{Mn}_2\text{O}_7$. *Science* **273**, 81–84 (1996).
- Ramirez, A. P., Cava, R. J. & Krajewski, J. Colossal magnetoresistance in Cr-based chalcogenide spinels. *Nature* **386**, 156–159 (1997).
- Jonker, G. H. & van Santen, J. H. Ferromagnetic compounds of manganese with perovskite structure. *Physica* **16**, 337–349 (1950).
- Zener, C. Interaction between the d -shells in the transition metals. II. Ferromagnetic compounds of manganese with perovskite structure. *Phys. Rev.* **82**, 403–405 (1951).
- Anderson, P. W. & Hasegawa, H. Considerations on double exchange. *Phys. Rev.* **100**, 675–681 (1955).
- de Gennes, P.-G. Effects of double exchange in magnetic crystals. *Phys. Rev. B* **118**, 141–154 (1960).
- Furukawa, N. Transport properties of the Kondo lattice model in the limit $S = \infty$ and $D = \infty$. *J. Phys. Soc. Jpn* **63**, 3214–3217 (1994).
- Hwang, H. Y., Cheong, S.-W., Radaelli, P. G., Marezio, M. & Batlogg, B. Lattice effects on the magnetoresistance in doped LaMnO_3 . *Phys. Rev. Lett.* **75**, 914–917 (1995).
- Hundley, M. F. *et al.* Transport-magnetism correlations in the ferromagnetic oxide $\text{La}_{0.7}\text{Ca}_{0.3}\text{MnO}_3$. *Appl. Phys. Lett.* **67**, 860–862 (1995).
- Hwang, H. Y., Cheong, S.-W., Ong, N. P. & Batlogg, B. Spin-polarised intergrain tunnelling in $\text{La}_{2/3}\text{Sr}_{1/3}\text{MnO}_3$. *Phys. Rev. Lett.* **77**, 2041–2044 (1996).
- Gupta, A. *et al.* Grain-boundary effects on the magnetoresistance properties of perovskite manganite films. *Phys. Rev. B* **54**, R15629–R15632 (1996).
- Snyder, G. J., Hiskes, R., DiCaroli, S., Beasley, M. R. & Geballe, T. H. Intrinsic electrical transport and magnetic properties of $\text{La}_{0.67}\text{Ca}_{0.33}\text{MnO}_3$ and $\text{La}_{0.67}\text{Sr}_{0.33}\text{MnO}_3$ MOCVD thin films and bulk material. *Phys. Rev. B* **53**, 14434–14444 (1996).
- Lu, Y. *et al.* Large magnetotunnelling effect at low magnetic fields in micrometer-scale epitaxial $\text{La}_{0.67}\text{Sr}_{0.33}\text{MnO}_3$ tunnel junctions. *Phys. Rev. B* **54**, R8357–R8360 (1996).
- Sun, J. Z. *et al.* Observation of large low-field magnetoresistance in trilayer perpendicular transport devices made using doped manganite perovskites. *Appl. Phys. Lett.* **69**, 3266–3268 (1996).
- Dimos, D., Chaudhari, P. & Mannhart, J. Superconducting transport-properties of grain-boundaries in $\text{YBa}_2\text{Cu}_3\text{O}_7$ bicrystals. *Phys. Rev. B* **41**, 4038–4049 (1990).
- Beck, A. *et al.* Fabrication and superconducting transport properties of bicrystal grain boundary Josephson junctions on different substrates. *IEEE Trans. Appl. Supercond.* **5**, 2192–2195 (1995).
- McCormack, M. *et al.* Very large magnetoresistance in perovskite-like La–Ca–Mn–O thin films. *Appl. Phys. Lett.* **64**, 3045–3047 (1994).
- Sun, J. Z., Krusin-Elbaum, L., Parkin, S. S. P. & Xiao, G. Transport and magnetic properties of *in situ* grown thin-film La–Y–Ca–Mn–O. *Appl. Phys. Lett.* **67**, 2726–2728 (1995).
- Xiong, G. *et al.* Giant magnetoresistance in epitaxial $\text{Nd}_{0.7}\text{Sr}_{0.3}\text{MnO}_{3-\delta}$ thin films. *Appl. Phys. Lett.* **66**, 1427–1429 (1995).
- Parkin, S. S. P., Bhadra, R. & Roche, K. P. Oscillatory magnetic exchange coupling through thin copper layers. *Phys. Rev. Lett.* **66**, 2152–2155 (1991).
- Dieny, B. Classical-theory of giant magnetoresistance in spin-valve multilayers—Influence of thicknesses, number of periods, bulk and interfacial spin-dependent scattering. *J. Phys. Condens. Matter* **4**, 8009–8020 (1992).

Acknowledgements. We thank Z. H. Barber, W. E. Booi, M. J. Hall, S. Kovtonyuk, D. B. Jardine, D.-J. Kang, E. J. Tarte, Y. S. Soman and R. E. Somekh. This work was supported by the UK EPSRC through the Advanced Magnetism Programme.

Correspondence and requests for materials should be addressed to N.D.M. (e-mail: ndm12@cus.cam.ac.uk).

Synthesis of epothilones A and B in solid and solution phase

K. C. Nicolaou*, N. Winssinger*, J. Pastor*, S. Ninkovic*, F. Sarabia*, Y. He*, D. Vourloumis*, Z. Yang*, T. Li, P. Giannakakou† & E. Hamel‡

* Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA, and Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA

† Medicine Branch, DCS, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA

‡ Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, DCTDC, NCI, Frederick Cancer Research and Development Center, Frederick, Maryland 21702, USA

Epothilones A and B, two compounds that have been recently isolated¹ from myxobacterium *Sorangium cellulosum* strain 90, have generated intense interest^{2–16} among chemists, biologists and clinicians owing to the structural complexity, unusual mechanism of interaction with microtubules and anticancer potential of these molecules. Like taxol* (refs 17, 18), they exhibit cytotoxicity against tumour cells by inducing microtubule assembly and stabilization^{3,4}, even in taxol-resistant cell lines. Following the structural elucidation of these molecules by X-ray crystallography in 1996¹, several syntheses of epothilones A (refs 12–16) and B (ref. 19) have been reported, indicative of the potential importance of these molecules in the cancer field. Here we report the first solid-phase synthesis of epothilone A, the total synthesis of epothilone B, and the generation of a small epothilone library. The solid-phase synthesis applied here to epothilone A could open up new possibilities in natural-product synthesis and, together with solution-phase synthesis of other epothilones, paves the way for the generation of large combinatorial libraries of these important molecules for biological screening.

The strategy for the solid-phase synthesis of epothilone A (1) was based on the retrosynthetic analysis indicated in Fig. 1 (refs 5, 13). Thus, it was anticipated that the three requisite fragments (5–7), one on a solid support (7), would be coupled together sequentially through an aldol reaction, an esterification reaction, and an olefin metathesis reaction^{20–25}, the latter simultaneously cyclizing and liberating the product from the solid support (6 + 7 + 5 ! 3). A simple desilylation and epoxidation reaction would then complete the total synthesis of epothilone A (1) and analogues thereof (3 ! 1). The outlook for obtaining two products at each of the aldol, metathesis and epoxidation steps was considered advantageous for the purposes of library generation.

Merrifield resin (8, Fig. 2) was converted to phosphonium salt 9 in >90% yield by sequential reaction with: (1) 1,4-butanediol-NaH-*n*-Bu₄NI cat.; (2) Ph₃P-iodine-imidazole; and (3) Ph₃P (for abbreviations see figure legends). Ylide 10²⁶, generated from 9 by the action of NaHMDS in THF:DMSO at 25 °C, reacted with aldehyde 11 (K.C.N. *et al.*, unpublished results) at 0 °C to form olefinic compound 12 in >70% yield. The geometry of the double bond in 12 was tentatively¹⁴ assigned as *Z*, but its geometry was neither rigorously determined nor did it matter for our purposes. Desilylation of 12 with HF·pyridine, followed by Swern oxidation of the resulting primary alcohol furnished aldehyde 7 in high yield (>95%). The aldol condensation of the polymer-bound aldehyde 7 with the dianion derived from keto acid 6 in the presence of ZnCl₂ in tetrahydrofuran (THF) gave a mixture of diastereoisomers

* Bristol-Myers Squibb has registered Taxol as a trademark and wishes the scientific community to use the name paclitaxel.

Figure 1 Retrosynthetic analysis of epothilone A (**1**) by a solid-phase olefin metathesis strategy. TBS, *t*-BuMe₂Si; the shaded circle indicates polystyrene.

Figure 2 (a) 1,4-butanediol (5.0 equiv.), NaH (5.0 equiv.), *n*-Bu₄NI (0.1 equiv.), DMF, 25°C, 12 h; (b) Ph₃P (4.0 equiv.), I₂ (4.0 equiv.), imidazole (4.0 equiv.), CH₂Cl₂, 25°C, 3 h; (c) Ph₃P (10 equiv.), 90°C, 12 h (>90% for 3 steps based on mass gain of polymer); (d) NaHMDS (3.0 equiv.), THF:DMSO (1:1), 25°C, 12 h; (e) **11** (2.0 equiv.), THF, 0°C, 3 h (>70% based on aldehyde recovered from ozonolysis); (f) 10% HF-pyridine in THF, 25°C, 12 h; (g) (COCl)₂ (4.0 equiv.), DMSO (8.0 equiv.), Et₃N (12.5 equiv.), -78! -25°C (estimated yield ~95% for 2 step; the reaction was monitored by IR analysis of polymer-bound material and by TLC analysis of the products obtained by ozonolysis); (h) **6** (2.0 equiv.), LDA (2.2 equiv.), THF, -78! -40°C, 1 h; then add resulting enolate to the resin suspended in a ZnCl₂ (2.0 equiv.) solution in THF, -78! -40°C, 2 h (~90%; estimated yield, as step g); (i) **5**, (5.0 equiv.), DCC (5.0 equiv.), 4-DMAP (5.0 equiv.), 25°C, 15 h (80% yield as determined by recovered heterocycle fragments obtained by treatment with NaOMe); (j) **15** (0.75 equiv.), CH₂Cl₂, 25°C, 48 h (52%); **16**: **17**: **18**: **3** = ~3:3:1:3; (k) 20% TFA in CH₂Cl₂ (v/v), 92% for **19** and 90% for **20**; (l) **22** [methyl(trifluoromethyl)dioxirane, acetonitrile], 0°C, 2 h (70% for **1**, 45% for **21**; in addition to these products, the corresponding α-epoxides were

also obtained). NaHMDS, sodium bis(trimethylsilyl)amide; DMSO, dimethyl sulphoxide; LDA, lithium diisopropylamide; TBS, *t*-BuMe₂Si; 4-DMAP, 4-dimethylaminopyridine; TFA, trifluoroacetic acid. Selected physical data for compound **20**: ¹H NMR (400 MHz, CDCl₃) δ 6.95 (s, 1 H, ArH), 6.59 (s, 1 H, ArCH = C(CH₃)), 5.44 (ddd, *J* = 10.5, 10.5, 4.5 Hz, 1 H, CH = CHCH₂), 5.36 (ddd, *J* = 10.5, 10.5, 5.0 Hz, 1 H, CH = CHCH₂), 5.28 (d, *J* = 9.4 Hz, 1 H, CO₂CH), 4.23 (d, *J* = 11.1 Hz, 1 H, (CH₃)₂CCl-H(OH)), 3.72 (m, CHOH(CHCH₃)), 3.43-3.37 (m, 1 H, OH), 3.14 (q, *J* = 6.7 Hz, 1 H, CH₃CH(C = O)), 3.05 (bs, 1 H, OH), 2.72-2.63 (m, 1 H), 2.69 (s, 3 H, CH₃Ar), 2.48 (dd, *J* = 14.8, 11.3 Hz, 1 H, CH₂COO), 2.33 (dd, *J* = 14.8, 2.0 Hz, 1 H, CH₂COO), 2.30-2.13 (m, 2 H) 2.07 (s, 3 H, ArCH = CCH₃), 2.07-1.98 (m, 1 H), 1.80-1.60 (m, 2 H), 1.32 (s, 3 H, C(CH₃)₂), 1.36-1.13 (m, 3 H), 1.17 (d, *J* = 6.8 Hz, 3 H, CH₃CH(C = O)), 1.06 (s, 3 H, C(CH₃)₂), 0.99 (d, *J* = 7.0 Hz, 3 H, CH₃CHCH₂). ¹³C NMR (150.9 MHz, CDCl₃) δ 220.6, 170.4, 165.0, 151.9, 138.7, 133.4, 125.0, 119.4, 115.8, 78.4, 74.1, 72.3, 53.3, 41.7, 39.2, 38.5, 32.4, 31.7, 27.6, 27.4, 22.7, 19.0, 18.6, 15.9, 15.5, 13.5; infrared (thin film) ν_{max} 3,453, 2,929, 1,733, 1,686, 1,506, 1,464, 1,250, 978 cm⁻¹; [α]_D²⁵ -80.2 (c 1.36, CHCl₃); HRMS (FAB), calc. for C₂₆H₃₉CSNO₅S (M + Cs⁺) 610.1603, found 610.1580.

The total synthesis of epothilone B (**2**) followed a strategy derived from the retrosynthetic analysis shown in Fig. 3¹⁴. This strategy called for coupling of intermediates **6**, **25** and **26** via a Wittig olefination, an aldol reaction, and a macrolactonization, followed by epoxidation, and was expected to proceed via intermediates **24** and **23**. This plan was deliberately chosen for its potential to deliver

The synthesized epothilones were tested for their action on tubulin assembly using purified tubulin with an assay²⁸ developed to amplify differences between compounds more active than taxol. As demonstrated in Fig. 5, both epothilone B (2) ($EC_{50} = 4.0 \pm 1 \mu M$; defined in Fig. 5 legend) and its progenitor **23** ($EC_{50} = 3.3 \pm 0.2 \mu M$) were significantly more active than taxol ($EC_{50} = 15.0 \pm 2 \mu M$) and epothilone A (1) ($EC_{50} =$

† The growth of all cell lines was evaluated by quantitation of the protein in microtitre plates⁴. The parental cell line 1A9, a clone of the A2780 cell line, was used to select two taxol resistant sublines (1A9PTX10 and 1A9PTX22)²⁹. These sublines were selected by growth in the presence of taxol and verapamil, a P-glycoprotein modulator. Two distinct point mutations in the β -tubulin isotype M40 gene were identified. In 1A9PTX10 amino acid residue 270 was changed from Phe (TTT) to Val (GTT), and in 1A9PTX22 residue 364 was changed from Ala (GCA) to Thr (ACA). The A2780AD line is a multi-drug resistant (MDR) line expressing high levels of P-glycoprotein³⁰. Relative resistance refers to the ratio of the IC₅₀ value obtained with a resistant cell line to that obtained with the parental cell line.

$14.0 \pm 0.4 \mu\text{M}$), whereas compounds **34**, **20** and **32** were less effective than taxol.

Preliminary cytotoxicity experiments with 1A9, 1A9PTX10 (β -tubulin mutant)²⁹, 1A9PTX22 (β -tubulin mutant)²⁹ and A2780AD cell lines revealed a number of interesting results (Table 1). Despite its high potency in the tubulin assembly assay, compound **23** did not display the potent cytotoxicity of **2** against 1A9 cells, being similar to **1** and taxol. These data suggest that whereas the C12-C13 epoxide is

not required for the epothilone-tubulin interaction, it may play an important role in localizing the agent to its target within the cell. Like the naturally occurring epothilones **1** and **2**, analogue **23** showed significant activity against the MDR line A2780AD and the altered β -tubulin-expressing cell lines 1A9PTX10 and 1A9PTX22, suggesting, perhaps, different contact points for the epothilones and taxol with tubulin (that is, stronger binding of epothilones around residue 364 than around 270 relative to taxoids).

Figure 4 (a) **25** (1.5 equiv.), NaHMDS (1.5 equiv.), THF, 0°C, 15 min; then add **26** (1.0 equiv.), -20°C, 12 h, 73% (*Z*:*E* = 1:1); (b) CSA (1.0 equiv.), CH₂Cl₂:MeOH (1:1), 0°C, 1 h; then 25°C, 0.5 h, 97%; (c) SO₃:pyr. (2.0 equiv.), DMSO (10 equiv.), Et₃N (5 equiv.), CH₂Cl₂, 25°C, 0.5 h, 95%; (d) LDA (3.0 equiv.), THF, 0°C, 15 min; then **6** (1.2 equiv. in THF), -78°C, -40°C, 0.5 h; then **28** (1.0 equiv. in THF), -78°C; (e) TBSOTf (3.0 equiv.), 2,6-lutidine (5.0 equiv.), CH₂Cl₂, 0°C, 2 h; (f) K₂CO₃ (2.0 equiv.), MeOH, 25°C, 15 min, 31% of **29** from **28** and 30% of **29a** from **28**; (g) TBAF (6.0 equiv.), THF, 25°C, 8 h, 75%; (h) 2,4,6-trichlorobenzoylchloride (2.0 equiv.), Et₃N (2.0 equiv.), THF, 0°C, 1 h; then add to a solution of 4-DMAP (10.0 equiv. in toluene, 0.002 M), 25°C, 12 h, 40% of **30** and 37% of **31**; (i) 20% TFA (by volume) in CH₂Cl₂, -10°C, 1 h, 89%; (j) same as i, 91%; (k) methyl(trifluoromethyl) dioxirane, acetonitrile, 0°C, 86% (**33**:**34** ~1:1 diastereoisomers) or *m*CPBA (1.5 equiv.), benzene, 3°C, 2 h, 73% (**33**:**34** ~4:1 ratio of stereoisomers); (l) methyl(trifluoromethyl)dioxirane, acetonitrile, 0°C, 85% (**2**:**35** ~5:1 ratio of diastereoisomers) or *m*CPBA (1.5 equiv.), benzene, 3°C, 2 h, 66% (**2**:**35** ~5:1 ratio of diastereoisomers); NaHMDS, sodium bis(trimethylsilyl)amide; CSA, camphorsulphonic acid; DMSO, dimethyl sulphoxide; LDA, lithium diisopropylamide; TBS,*t*-

BuMe₂Si; TBSOTf, *t*-BuMe₂SiOSO₂CF₃; TBAF, tetra-*n*-butylammonium fluoride; 4-DMAP, 4-dimethylaminopyridine; *m*CPBA, 3-chloroperoxybenzoic acid; TFA, trifluoroacetic acid. Selected physical data for compound **23**: ¹H NMR (600 MHz, CDCl₃) δ 6.94 (s, 1 H, SCH = C), 6.57 (s, 1 H, CH = CCH₃), 5.20 (d, *J* = 9.7 Hz, 1 H, CH₂COOCH), 5.13 (dd, *J* = 9.6, 4.6 Hz, 1 H, CH₂C = CHCH₂), 4.28 (d, *J* = 9.7 Hz, 1 H, (CH₃)₂CCHOH), 3.71 (s, 1 H, CHOH), 3.47 (bs, 1 H, OH), 3.15 (q, *J* = 6.8 Hz, 1 H, C(O)CHCH₃), 3.04 (bs, 1 H, OH), 2.68 (s, 3 H, N = C(CH₃)S), 2.62 (ddd, *J* = 15.0, 10.2, 10.1 Hz, 1 H, CH₂CH = CCH₃), 2.45 (dd, *J* = 14.7, 11.1 Hz, 1 H, CH₂COOCH), 2.38-2.24 (m, 1 H), 2.28 (dd, *J* = 14.8, 2.2 Hz, CH₂COOCH), 2.22 (d, *J* = 14.9 Hz, 1 H, CH₂C(CH₃) = CHCH₂), 2.06 (s, 3 H, CH = CCH₃), 1.90-1.84 (m, 1 H), 1.76-1.69 (m, 1 H), 1.65 (s, 3 H, CH₂C(CH₃) = CH), 1.33 (s, 3 H, C(CH₃)₂), 1.32-1.22 (m, 4 H), 1.19 (d, *J* = 6.8 Hz, 3 H, CH(CH₃)), 1.06 (s, 3 H, C(CH₃)₂), 1.00 (d, *J* = 7.0 Hz, 3 H, CH(CH₃)); ¹³C NMR (150.9 MHz, CDCl₃) δ 220.4, 170.2, 164.9, 151.8, 139.1, 138.3, 120.8, 119.1, 115.5, 78.9, 74.1, 72.3, 53.6, 41.7, 39.7, 32.6, 31.8, 31.7, 25.4, 23.0, 19.1, 18.1, 16.0, 15.8, 13.5; infrared (thin film) ν_{max} 3,460, 2,954, 2,919, 1,725, 1,684, 1,455, 1,379, 1,290, 1,249, 1,184, 1,143, 1,043, 1,008, 973, 750 cm⁻¹; [α]_D²⁵ -91.5 s, (c 0.3, CHCl₃); HRMS (FAB) *m/e* 492.2795, (M + H⁺) calc. for C₂₇H₄₁NO₅S 492.2784.

Figure 5 The tubulin assembly assay was performed essentially as described previously²⁸. Reaction mixtures contained purified tubulin at 1.0 mg ml⁻¹, 0.4 M monosodium glutamate, 5% dimethyl sulphoxide, and varying drug concentrations. Each compound was evaluated in three different experiments and average values are shown. The EC₅₀ is defined as the drug concentration that causes 50% of the tubulin to assemble into polymer. In the absence of drug, <5% of the tubulin was removed by centrifugation, while with high concentrations of the most active drugs, >95% of the protein formed polymer. This suggests that at least 90% of the tubulin had the potential to interact with epothilones and taxoids. Although the EC₅₀ value obtained for taxol was higher than that obtained in an alternate assay³, the agent's role in these experiments was only as a control. The numbers on the curves correspond to compound numbers in the text.

The solid-phase synthesis of epothilone A (**1**) described here represents a new concept for the total synthesis of natural products, traces a highly efficient pathway to the naturally occurring epothilones, and opens the way for the generation of large combinatorial epothilone libraries. The biological results demonstrate that more potent microtubule binding analogues than the parent epothilones can be obtained (for example, compound **23**) by chemical synthesis. Furthermore, our findings point to lipophilic substituents rather than the epoxide moiety as important elements for binding activity. The role of the epoxide in the cytotoxicity of epothilones, however, still remains to be elucidated. □

Received 3 April; accepted 17 April 1997.

- Höfle, G. *et al.* Epothilone A and B—novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution. *Angew. Chem. Int. Edn. Engl.* **35**, 1567–1569 (1996).
- Grever, M. R., Schepartz, S. A. & Chabner, B. A. The national cancer institute: cancer drug discovery and development program. *Semin. Oncol.* **19**, 622–638 (1992).
- Bollag, D. M. *et al.* Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. *Cancer Res.* **55**, 2325–2333 (1995).
- Kowalski, R. J., Giannakakou, P. & Hamel, E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). *J. Biol. Chem.* **272**, 2534–2541 (1997).
- Nicolaou, K. C., He, Y., Vourloumis, D., Vallberg, H. & Yang, Z. An approach to epothilones based on olefin metathesis. *Angew. Chem. Int. Edn. Engl.* **35**, 2399–2401 (1996).
- Meng, D., Sorensen, E. J., Bertinato, P. & Danishefsky, S. J. Studies toward a synthesis of epothilone A: use of hydropyran templates for the management of acyclic stereochemical relationships. *J. Org. Chem.* **61**, 7998–7999 (1996).
- Bertinato, P., Sorensen, E. J., Meng, D. & Danishefsky, S. J. Studies toward a synthesis of epothilone A: stereocontrolled assembly of the acyl region and models for macrocyclization. *J. Org. Chem.* **61**, 8000–8001 (1996).
- Schinzler, D., Limberg, A. & Böhm, O. M. Studies toward the total synthesis of epothilones: asymmetric synthesis of the key fragments. *Chem. Eur. J.* **2**, 1477–1482 (1996).
- Mulzer, J. & Mantoulidis, A. Synthesis of the C(1)–C(9) segment of the cytotoxic macrolides epothilone A and B. *Tetrahedr. Lett.* **37**, 9179–9182 (1996).
- Claus, E., Pahl, A., Jones, P. G., Meyer, H. M. & Kalesse, M. Synthesis of the C1–C9 segment of epothilones. *Tetrahedr. Lett.* **38**, 1359–1362 (1997).
- Gabriel, T. & Wessjohann, L. The Chromium-Reformatsky reaction: asymmetric synthesis of the aldol fragment of the cytotoxic epothilones from 3-(2-bromoacyl)-2-oxazolidinones. *Tetrahedr. Lett.* **38**, 1363–1366 (1997).
- Balog, A. *et al.* Total synthesis of (–)-epothilone A. *Angew. Chem. Int. Edn. Engl.* **35**, 2801–2803 (1996).
- Yang, Z., He, Y., Vourloumis, D., Vallberg, H. & Nicolaou, K. C. Total synthesis of epothilone A: the olefin metathesis approach. *Angew. Chem. Int. Edn. Engl.* **36**, 166–168 (1997).
- Nicolaou, K. C., Sarabia, F., Ninkovic, S. & Yang, Z. Total synthesis of epothilone A: the macro-lactonization approach. *Angew. Chem. Int. Edn. Engl.* **36**, 525–527 (1997).
- Schinzler, D., Limberg, A., Bauer, A., Böhm, O. M. & Cordes, M. Total synthesis of (–)-epothilone A. *Angew. Chem. Int. Edn. Engl.* **36**, 523–524 (1997).
- Meng, D. *et al.* Remote effects in macrolide formation through ring-forming olefin metathesis: an application to the synthesis of fully active epothilone congeners. *J. Am. Chem. Soc.* **119**, 2733–2734 (1997).
- Horwitz, S. B., Fant, J. & Schiff, P. B. Promotion of microtubule assembly *in vitro* by taxol. *Nature* **277**, 665–667 (1979).
- Nicolaou, K. C., Dai, W.-M. & Guy, R. K. The chemistry and biology of Taxol. *Angew. Chem. Int. Edn. Engl.* **33**, 15–44 (1994).
- Su, D.-S. *et al.* Total synthesis of (–)-epothilone B: an extension of the Suzuki coupling method and insights into structure-activity relationships of the epothilones. *Angew. Chem. Int. Edn. Engl.* **36**, 757–759 (1997).
- Grubbs, R. H., Miller, S. J. & Fu, G. C. Ring-closing metathesis and related processes in organic synthesis. *Acc. Chem. Res.* **28**, 446–452 (1995).
- Miller, S. J., Blackwell, H. E. & Grubbs, R. H. Application of ring-closing metathesis to the synthesis of rigidified amino acids and peptides. *J. Am. Chem. Soc.* **118**, 9606–9614 (1996).
- Xu, Z., Johannes, C. W., Salman, S. S. & Hoveyda, A. H. Enantioselective total synthesis of antifungal agent Sch 38516. *J. Am. Chem. Soc.* **118**, 10926–10927 (1996).
- van Maarseveen, J. H. *et al.* Solid phase ring-closing metathesis: cyclization/cleavage approach towards a seven membered cycloolefin. *Tetrahedr. Lett.* **37**, 8249–8252 (1996).
- Miller, J. F., Termin, A. & Piscopio, A. D. Ester enolate Claisen-ring closing metathesis route to functionalized carbocycles and heterocycles. Presented at 213th Am. Chem. Soc. Natl Meeting, San Francisco. 13–17 April (1997).
- Schuster, M., Pernerstorfer, J. & Bleichert, S. Ruthenium-catalyzed metathesis of polymer-bound olefins. *Angew. Chem. Int. Edn. Engl.* **35**, 1979–1980 (1996).
- Bernard, M. & Ford, W. T. Wittig reagents bound to cross-linked polystyrenes. *J. Org. Chem.* **48**, 326–332 (1983).
- Yang, D., Wong, M.-K. & Yip, Y.-C. Epoxidation of olefins using methyl(trifluoromethyl)dioxirane generated *in situ*. *J. Org. Chem.* **60**, 3887–3889 (1995).
- Lin, C. M. *et al.* A convenient tubulin-based quantitative assay for paclitaxel (Taxol) derivatives more effective in inducing assembly than the parent compound. *Cancer Chemother. Pharmacol.* **38**, 136–140 (1996).
- Giannakakou, P. *et al.* Paclitaxel resistant human ovarian cancer cells have mutant β -tubulins that exhibit impaired paclitaxel driven polymerization. *J. Biol. Chem.* (in the press).
- Rogan, A. M. *et al.* Reversal of adriamycin resistance by verapamil in human ovarian cancer. *Science* **244**, 994–996 (1984).

Acknowledgements. We thank G. Höfle and Merck Research Laboratories for gifts of epothilones A and B; and D. H. Huang and G. Siuzdak for NMR and mass spectroscopic assistance, respectively. This work was supported by the NIH, The Skaggs Institute for Chemical Biology and the CaP CURE Foundation, and fellowships from the Ministerio de Educación y Ciencia (Spain) (J.P.), Fundación Ramón Areces (Spain) (F.S.) and Novartis (D.V.), and grants from Merck, DuPont-Merck, Schering Plough, Hoffmann La Roche and Amgen.

Correspondence and requests for materials should be addressed to K.C.N. at Scripps Research Institute.

Evolution of the nitrogen cycle and its influence on the biological sequestration of CO₂ in the ocean

Paul G. Falkowski

Oceanographic and Atmospheric Sciences Division, Brookhaven National Laboratory, Upton, New York 11973, USA

Over geological time, photosynthetic carbon fixation in the oceans has exceeded respiratory oxidation of organic carbon. The imbalance between the two processes has resulted in the simultaneous accumulation of oxygen in, and drawdown of carbon dioxide from, the Earth's atmosphere, and the burial of organic carbon in marine sediments^{1–3}. It is generally assumed that these processes are limited by the availability of phosphorus^{4,5}, which is supplied by continental weathering and fluvial discharge^{5–7}. Over the past two million years, decreases in atmospheric carbon dioxide concentrations during glacial periods correlate with increases in the export of organic carbon from surface waters to the marine sediments^{8–11}, but variations in phosphorus fluxes appear to have been too small to account for these changes^{12,13}. Consequently, it has been assumed that total oceanic primary productivity remained relatively constant during glacial-to-interglacial transitions, although the fraction of this productivity exported to the sediments somehow increased during glacial periods^{12,14}. Here I present an analysis of the evolution of biogeochemical cycles which suggests that fixed nitrogen, not phosphorus, limits primary productivity on geological timescales. Small variations in the ratio of nitrogen fixation to denitrification can significantly change atmospheric carbon dioxide concentrations on glacial-to-interglacial timescales. The ratio of these two processes appears to be determined by the oxidation state of the ocean and the supply of trace elements, especially iron.

Globally, nitrogen and phosphorus are the two elements that potentially limit the biologically mediated carbon assimilation in the oceans by photoautotrophs. It is frequently argued that, as N₂ is abundant in both the ocean and atmosphere, and, in principle, can be biologically reduced to the equivalent of NH₃ by N₂-fixing cyanobacteria (that is, diazotrophs), nitrogen cannot be limiting on geological timescales^{4,15,16}. It then follows that phosphorus, which has no significant atmospheric source, must ultimately limit biological productivity. The underlying assumptions of these tenets should, however, be considered within the context of the evolution of biogeochemical cycles and the manifestations of those cycles in the contemporary ocean.

Virtually all fixed inorganic nitrogen in the contemporary ocean is oxidized to nitrate. Where did the nitrate come from? Although, in the Archaean atmosphere, electrical discharge or bolide impacts might have promoted NO formation from reaction between N₂ and CO₂, the yield for the reaction is low¹⁷. NH₃ in the Archaean atmosphere would have photodissociated, driven by ultraviolet radiation¹⁷; however, N₂ would have been stable and abundant^{17,18}. N₂ can be biologically reduced to NH₃ via the enzyme nitrogenase. Biological N₂ fixation is a strictly anaerobic process¹⁹, and the sequence of the genes encoding the catalytic subunits for nitrogenase is highly conserved in cyanobacteria and other eubacteria, strongly suggesting an ancient, common ancestral origin²⁰. The antiquity and homology of nitrogen fixation capacity also implies that fixed inorganic nitrogen in the Archaean and early Protozoic oceans was scarce before the evolution of diazotrophic organisms; that is, there was strong evolutionary selection for N₂ fixation.